{"pub_date": "2016-02-06T00:00:00Z", "subsection_name": null, "lead_paragraph": "Marc Tessier-Lavigne, who will leave Rockefeller University to lead Stanford University, has also worked as an executive in the biotech industry,", "print_page": "15", "document_type": "article", "byline": {"contributor": "Andrew Pollack contributed reporting.", "person": [{"rank": 1, "organization": "", "lastname": "SAUL", "firstname": "Stephanie", "role": "reported"}], "original": "By STEPHANIE SAUL"}, "multimedia": [], "section_name": "U.S.", "headline": {"print_headline": "New Stanford President Has Biotech Connection ", "main": "New Stanford President Has Biotech Connection "}, "source": "The New York Times", "blog": [], "word_count": "730", "web_url": "http://www.nytimes.com/2016/02/06/us/marc-tessier-lavigne-new-stanford-president.html", "slideshow_credits": null, "news_desk": "National", "type_of_material": "News", "snippet": "Marc Tessier-Lavigne, who will leave Rockefeller University to lead Stanford University, has also worked as an executive in the biotech industry,", "_id": "56b5547a38f0d86b498f99da", "abstract": "Interview with incoming Stanford University president Marc Tessier-Lavigne reveals that his position on board of biotech company Juno Therapeutics will be reviewed to make sure no conflicts of interest exist.", "keywords": [{"rank": "1", "name": "persons", "value": "Tessier-Lavigne, Marc", "is_major": "Y"}, {"rank": "2", "name": "subject", "value": "Colleges and Universities", "is_major": "Y"}, {"rank": "3", "name": "organizations", "value": "Juno Therapeutics Inc", "is_major": "Y"}, {"rank": "4", "name": "organizations", "value": "Rockefeller University", "is_major": "N"}, {"rank": "5", "name": "subject", "value": "Appointments and Executive Changes", "is_major": "N"}, {"rank": "6", "name": "subject", "value": "Biotechnology and Bioengineering", "is_major": "N"}, {"rank": "7", "name": "organizations", "value": "Stanford University", "is_major": "Y"}]}